secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2022-03-25T23:59:59+00:00
Accession:  0001193125-22-085330
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed CFO David Guebert retiring Mar 31; director Vinson not seeking re-election; exec comp increases
--------------------------------------------------------------------------------

- CFO David Guebert's last day is March 31, 2022; search for new CFO launched with executive search firm.
- Director Sarah Y. Vinson will not stand for re-election at 2022 Annual Meeting; no disagreement cited.
- Board reduces size from 6 to 5 effective at 2022 Annual Meeting.
- CEO Robert Barrow base salary increased to $565,000, plus $233,411 cash bonus and equity awards.
- Executive President Miri Halperin Wernli base salary raised to $390,000 with 40% target bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/d314752d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-085330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer